Shares in Arrowhead Pharmaceuticals (ARWR 0.72%) rose by more than 27% in the week to Friday morning. The company's bold aim is to have "20 individual products, either partnered or wholly owned, in clinical trials or on the market by 2025," and the company moved a step closer to that aim with the signing of a global licensing and collaboration agreement with pharmaceutical giant Novartis for AR...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Citi's 2025 Biopharma Back to School Conference September 3, 2025 1:00 PM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conference Call Participants David Lebowitz - Citigroup Inc., Research Division Presentation David Lebowitz Research Analyst Very much and welcome again to the Citi Biopharma Conference in Boston. H...
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for plozasiran showed robust efficacy in reducing triglycerides and acute pancreatitis risk, leading to an FDA PDUFA review date of November 18, 2025. Ongoing late-stage studies for severe hypertriglyc...
Arrowhead Pharmaceuticals said on Tuesday it will receive up to $2 billion from Novartis for an exclusive worldwide license to its experimental therapy that targets neuromuscular conditions such as Parkinson's Disease.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead's preclinical stage siRNA therapy against alpha-synuclein for the treatment of synucleinopathies, such as Parkinson's Disease, and for other additional collaboration targets that will utilize Arrowhead's ...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of Cardiology (ESC) Congress 2025 – August 29 - September 1, 2025 Title: A Randomized, Placebo-controlled Phase 3 Study of Plozasiran in Patients With FCS: Interim Analysis of Open Label Extension of PA...
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has elected to receive approximately $50 million worth of Arrowhead common stock and approximately $50 million in cash from Sarepta Therapeutics, satisfying the payment of a $100 million milestone owed to Arrowhead. This agreement pertains only to the $100 million milestone, which...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.